Sotera Health Co (SHC) Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing. Through its Nelson Labs division, Sotera Health conducts comprehensive microbiological and analytical chemistry analyses. Additionally, it offers specialized consulting to the medical device and biopharmaceutical industries. Sotera Health serves a diverse array of sectors, including medical device manufacturers, pharmaceutical companies, producers of food and agricultural products, and various commercial, advanced, and specialty application industries. Incorporated in 2017, the company was previously known as Sotera Health Topco, Inc., adopting its current name in October 2020.
Sector: Services-Misc Health & Allied Services, NEC
Industry: Medical - Diagnostics & Research
Sotera Health Company NASDAQ:SHC Healthcare · Medical - Diagnostics & Research
CLOSED · Nov 6 $16.01 CLOSED · Nov 6 Prev close $15.87 Close $16.01 0.00% AH close $16.01 VOL 2.2M $ Vol $34.99M RVOL 0.86x
Mkt Cap $4.57B
VOL 2.2M sh
$ Vol $34.99M
RVOL 0.86×
Press Release ⚠ 3
Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results
Sotera Health reported Q3 2026 net revenues of $324.9 million, up 4.4% year-over-year on both as-reported and constant currency bases, with net income of $58 million ($0.20 diluted EPS).
Adjusted EPS rose 12% to $0.29, and Adjusted EBITDA margin expanded nearly 100 basis points sequentially to 52.5%. Sterigenics grew 8.2% and Nelson Labs 9.2% in constant currency, while Nordion fell 11.5% on expected Co-60 harvest timing.
The company reaffirmed its FY2026 outlook of $1.233B-$1.250B revenue and $632M-$641M Adjusted EBITDA, and net leverage improved to 2.9x, within its 2.0x-3.0x target. A Moody's credit rating upgrade in early October followed the deleveraging progress.
• 5d ago AI analysis › Press Release
Sotera Health Announces Third-Quarter 2026 Earnings Release Date
Sotera Health will release third-quarter 2026 financial results before the market opens on Tuesday, November 3, 2026.
Management will host a conference call at 9:00 a.m. Eastern Time the same day, with a live webcast available via the company's Investor Relations site and a replay later that day.
The notice contains no financial figures or business updates; it also points investors to website resources covering recent developments, including Ethylene Oxide litigation-related matters.
• 18d ago AI analysis › Press Release ● Major
Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
Sotera Health reported Q2 2026 revenue of $321.4 million, up 9.2% year-over-year, with Adjusted EPS rising 30% to $0.26.
The company raised its full-year 2026 outlook, projecting constant currency revenue growth of 5.25% to 6.75% and Adjusted EBITDA growth of 5.75% to 7.25%.
Balance sheet strength improved with a Net Leverage Ratio of 3.0x, achieving the long-term target, alongside available liquidity of approximately $950 million.
• 3mo ago AI analysis › Press Release
Sotera Health Announces Second-Quarter 2026 Earnings Release Date
Sotera Health plans to announce its second-quarter 2026 financial results before the market opens on Thursday, August 6, 2026.
Management will host a conference call at 9:00 a.m. Eastern Time to discuss the company's operating and financial performance.
Investors are directed to the company's website for updates on recent developments, including information related to Ethylene Oxide.
• 3mo ago AI analysis › Press Release ⚠ 1
Sotera Health Announces Secondary Offering of Common Stock
Sotera Health announced a secondary offering of 31,838,253 shares of its common stock, all of which are being sold by affiliates of Warburg Pincus and GTCR.
The company will not receive any proceeds from the offering but will pay the expenses as per its Amended and Restated Registration Rights Agreement.
Goldman Sachs & Co. LLC is acting as the underwriter for the offering.
• 5mo ago AI analysis › Press Release
Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook
Sotera Health reported Q1 2026 net revenue of $280 million, up 10% year-over-year, swinging to a net income of $27 million compared to a $13 million loss in the prior year.
The company reaffirmed its full-year 2026 outlook, projecting 5.0% to 6.5% constant currency revenue growth and 5.5% to 7.0% Adjusted EBITDA growth.
Segment performance was mixed, with Sterigenics and Nordion delivering strong constant currency growth, while Nelson Labs saw a slight decline in revenue.
• 6mo ago AI analysis › Press Release
Sotera Health Announces Leadership Transition
Sotera Health announced a planned leadership transition appointing Alton Shader as the new CEO effective May 26, 2026, succeeding Michael B. Petras, Jr.
Mr. Petras will transition to the role of Executive Chairman and remain a full-time employee, assisting with commercial strategy, investor relations, and litigation matters.
Mr. Shader joins from Viant Medical, bringing over 20 years of experience in the medical device industry, including roles at Hill-Rom and Baxter International.
• 6mo ago AI analysis › 
